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Abstract
Background: In Switzerland, health policies are decided at the local level, but little is known regarding their
impact on the screening and management of cardiovascular risk factors (CVRFs). We thus aimed at assessing
geographical levels of CVRFs in Switzerland.
Methods: Swiss Health Survey for 2007 (N = 17,879). Seven administrative regions were defined: West (Leman), West-
Central (Mittelland), Zurich, South (Ticino), North-West, East and Central Switzerland. Obesity, smoking, hypertension,
dyslipidemia and diabetes prevalence, treatment and screening within the last 12 months were assessed by interview.
Results: After multivariate adjustment for age, gender, educational level, marital status and Swiss citizenship, no
significant differences were found between regions regarding prevalence of obesity or current smoking. Similarly,
no differences were found regarding hypertension screening and prevalence. Two thirds of subjects who had been
told they had high blood pressure were treated, the lowest treatment rates being found in East Switzerland: odds-
ratio and [95% confidence interval] 0.65 [0.50-0.85]. Screening for hypercholesterolemia was more frequently
reported in French (Leman) and Italian (Ticino) speaking regions. Four out of ten participants who had been told
they had high cholesterol levels were treated and the lowest treatment rates were found in German-speaking
regions. Screening for diabetes was higher in Ticino (1.24 [1.09 - 1.42]). Six out of ten participants who had been
told they had diabetes were treated, the lowest treatment rates were found for German-speaking regions.
Conclusions: In Switzerland, cardiovascular risk factor screening and management differ between regions and
these differences cannot be accounted for by differences in populations’ characteristics. Management of most
cardiovascular risk factors could be improved.
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Background
Coronary heart disease is one of the leading causes of death
worldwide and shows considerable geographical variation
[1,2]. This geographical variation can either be due to a
true difference in cardiovascular risk factor levels [3-5] or
to differences in cardiovascular risk factor management
[6-9], although other causes have been suggested [10].
In Switzerland, health policies are decided at the local
(canton) level. Further, with four official languages, Swit-
zerland is a country of large socio- cultural diversity,
which might also be reflected in health policies and
health expenditures [11]. Indeed, smoking policies differ
between cantons [12], and significant regional differ-
ences in glycemic control have also been reported
[13,14]. Hence, it is likely that these differing health
policies might lead to differences in cardiovascular risk
factor (CVRF) screening and management.
In this study, we used the data from the Swiss Health
Survey 2007 to assess the prevalence and management
of CVRFs according to geographical region.
Methods
Sampling
Data for the Swiss Health Survey (SHS) 2007 were
obtained from the Swiss federal bureau of statistics
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http://www.bfs.admin.ch. The SHS is a cross-sectional,
nationwide, population-based telephone survey con-
ducted every 5 years since 1992 by the Federal Statistical
Office of Switzerland under a mandate from the federal
government [15]. The data can be obtained upon
request and for selected purposes.
The study population was chosen by stratified random
sampling of a database of all private Swiss households
with fixed-line telephones (as opposed to mobile
phones). Switzerland has one of the highest coverage of
fixed phone lines in the world1 and over 90% of the
Swiss households have fixed telephones. The first sam-
pling stratum consisted of the seven main regions: West
“Leman”, West-Central “Mittelland”, Northwest, Zurich,
North-Eastern, Central and South (Ticino), see Figure 1.
The second stratum consisted of the cantons, and the
number of households drawn was proportional to the
population of the canton. In some cantons, oversam-
pling of households was performed to obtain accurate
cantonal estimates. The third stratum consisted of the
household. One member of the household was randomly
selected in advance within all members aged 15 years
and over. A letter inviting this selected household mem-
ber to participate in the survey was sent to each
sampled subject, who was contacted thereafter by phone
and interviewed using computer-assisted telephone
interview software to manage dialling and data collec-
tion. Face-to-face interviews were organised for subjects
older than 75 years. In the case of long-term absence of
a sampled subject, a proxy interviewee was requested to
provide answers on behalf of the pre-defined sampled
person (approximately 3% of households). The inter-
views were carried out in German, French or Italian, as
appropriate. People who did not speak any of these
three languages were excluded from the survey. Other
criteria for exclusion were asylum seeker status, house-
holds without a fixed-line telephone, very poor health
status and living in a nursing home [16]. The participa-
tion rate was 66%. It is estimated that < 2% of house-
holds were excluded owing to these exclusion criteria.
Details are available at http://www.bfs.admin.ch/bfs/por-
tal/fr/index/infothek/erhebungen__quellen/blank/blank/
ess/01.html. In this study, only adult (≥18 years) partici-
pants were considered.
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Figure 1 The seven administrative areas of Switzerland.
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Cardiovascular risk factors screening, prevalence and
management
Screening, prevalence and management of the main car-
diovascular risk factors was obtained by questionnaire
and was thus self-reported. Body mass index (BMI) was
computed from self-reported height and weight; over-
weight was considered for a BMI ≥25 and < 30 kg/m2;
obesity was considered for a BMI ≥30 kg/m2. Smoking
status was considered as current, former and never. Cur-
rent smokers were also asked if they had ever tried to
stop smoking for at least two weeks within the last 12
months, but were still considered as smokers in the sta-
tistical analysis.
Screening for hypertension, hypercholesterolemia or dia-
betes was present if the participant reported being
screened for this condition within the last 12 months. The
prevalence of hypertension, hypercholesterolemia or dia-
betes was considered if the participants provided a positive
answer to the questions: “Did a doctor or a health profes-
sional tell you that you have high blood pressure/a high
cholesterol level/diabetes?”, respectively. Subjects were
considered as being treated for hypertension, hypercholes-
terolemia or diabetes if they answered “daily”, “several
times per week” or “about once per week” to the questions
“During the last seven days, at what frequency did you
take medicines for blood pressure/to decrease your choles-
terol levels/for diabetes?”, respectively. When a participant
reported being treated but reported no risk factors, he/she
was considered as presenting with the risk factor.
Other variables
Marital status was grouped into single, married (or cohabi-
tating), divorced and widowed. Education was categorized
as follows: (i) no education completed/primary school
(referred to as ‘basic’); (ii) apprenticeship/secondary level
(referred to as ‘secondary’); and (iii) tertiary level, which
included university and other forms of education after the
secondary level (referred to as ‘university’). Nationality was
defined as Swiss/other. Attendance to a medical consulta-
tion within the last 12 months (yes/no) was also analyzed.
Statistical analysis
Statistical analysis was conducted using SAS v.9.2 (SAS
Inc., Cary, NC, USA). As some cantons are very small
(for example Appenzell Innerrhoden has only 15,000
inhabitants), it was not possible to directly assess differ-
ences between cantons. Hence, it was decided to use
regions, as they are administratively defined, aggregate
cantons with similar linguistic, geographical or cultural
characteristics, and provide an adequate number of parti-
cipants for analysis. These regions are the same which
were used for sampling stratification: West “Leman”,
West-Central “Mittelland”, Northwest, Zurich, North-
Eastern, Central and South (Ticino), see Figure 1. The
West “Leman” is a French-speaking region, the South
(Ticino) an Italian-speaking region, while the other
regions are in majority German-speaking.
Quantitative variables were expressed as mean ± stan-
dard deviation and qualitative variables as number of
participants and (percentage). Bivariate comparisons
were performed using analysis of variance (ANOVA) or
a chi-square test for quantitative and qualitative vari-
ables, respectively.
A first multivariate logistic regression analysis adjusting
for gender, age, marital status, educational level and Swiss
nationality was performed to compare between regions,
using Leman as a reference. For screening, a second analy-
sis with a further adjustment for BMI, smoking status and
attendance to medical consultation was also performed.
For prevalence, a second analysis with a further adjust-
ment for BMI, smoking status, attendance to medical con-
sultation and screening for the corresponding risk factor
was performed. The results were expressed as odds ratio
and 95% confidence intervals. Statistically significant dif-
ferences were considered when p < 0.05.
Results
Sample characteristics
Data from 17,879 participants (9862 women, mean age
50.4 ± 17.6 years) was collected. The clinical characteris-
tics of the participants according to the region are sum-
marized in Table 1. Participants living in Ticino were
older, while Zurich and Leman had the highest prevalence
of highly educated participants. A higher prevalence of
divorced participants was also found in these regions,
while the lowest prevalence of Swiss nationals was found
in Ticino and Leman. Finally, over three quarters of the
participants reported having consulted a doctor within the
last 12 months, the highest value being found in Leman
and the lowest in East Switzerland. Conversely, no differ-
ences were found regarding gender distribution between
regions (Table 1).
Obesity and smoking
The prevalences of obesity and smoking according to
region are summarized in Table 2. Mean BMI was lower
in Zurich and West-Central “Mittelland”, and these differ-
ences persisted after multivariate adjustment for age, gen-
der, education, nationality and marital status (Table 2).
Similarly, prevalence of obesity was lower in Zurich than
in West-Central “Mittelland”, but no significant between-
region differences in obesity levels were found after multi-
variate adjustment for age, gender, education, nationality
and marital status (Table 3).
Slightly more than one quarter of participants smoked,
the highest prevalence of smokers being found in Zurich
and East Switzerland, while the lowest values were
found in West-Central “Mittelland” and North-West
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Table 1 Main characteristics of the sample, overall and by region, 2007
Leman Mittelland North- West Zurich East Central Ticino Switzerland Test
Sample size 3332 4327 2262 2330 1900 2275 1453 17,879
Women (%) 1833 (55.0) 2393 (55.3) 1258 (55.6) 1270 (54.5) 1008 (53.1) 1266 (55.7) 834 (57.4) 9862 (55.2) 7.23NS
Age (years) 49.9 ± 17.6 50.3 ± 17.7 51.8 ± 17.5 50.8 ± 17.4 49.9 ± 17.6 49.3 ± 17.5 52.9 ± 17.9 50.4 ± 17.6 9.63***
Agea 52.1 ± 0.3 51.5 ± 0.3 53.7 ± 0.3 53.9 ± 0.3 52.1 ± 0.4 51.2 ± 0.3 54.3 ± 0.4 NA 18.39***
Educational level
Basic 518 (15.5) 695 (16.1) 247 (10.9) 196 (8.4) 242 (12.7) 314 (13.8) 259 (17.8) 2471 (13.8)
Secondary 1815 (54.5) 2548 (58.9) 1382 (61.1) 1310 (56.2) 1188 (62.6) 1395 (61.3) 885 (60.9) 10,523 (58.9) 229.2***
University 999 (30.0) 1084 (25.0) 633 (28.0) 824 (35.4) 470 (24.7) 566 (24.9) 309 (21.3) 4885 (27.3)
Marital status
Single 811 (24.3) 1030 (23.8) 562 (24.9) 695 (29.8) 489 (25.8) 584 (25.7) 324 (22.3) 4495 (25.2)
Married 1767 (53.1) 2309 (53.4) 1188 (52.5) 1071 (46.0) 1045 (55.1) 1258 (55.4) 794 (54.7) 9432 (52.8) 98.23***
Widowed 320 (9.6) 461 (10.7) 240 (10.6) 229 (9.8) 176 (9.3) 216 (9.5) 169 (11.6) 1811 (10.1)
Divorced 432 (13.0) 525 (12.1) 272 (12.0) 334 (14.4) 187 (9.9) 214 (9.4) 165 (11.4) 2129 (11.9)
Swiss nationality 2728 (81.9) 3899 (90.1) 1994 (88.2) 2009 (86.2) 1673 (88.1) 2077 (91.3) 1185 (81.6) 15,565 (87.1) 196.1***
Consulted last 12 m 2751 (82.6) 3507 (81.1) 1855 (82.0) 1883 (80.8) 1476 (77.7) 1802 (79.2) 1176 (80.9) 14,450 (80.8) 24.61***
Results are expressed as mean ± standard deviation, as adjusted mean ± standard error or as number of patients and (percentage). a adjusted for gender,
education, nationality and marital status. NA, not assessable. Statistical analysis by analysis of variance or chi-square test: NS; not significant; *, p < 0.05; **, p <
0.01; ***, p < 0.001
Table 2 Self-reported prevalence and screening the last 12 months of the main cardiovascular risk factors in
Switzerland, overall and by region, 2007
Leman Mittelland North- West Zurich East Central Ticino Switzerland Test
Sample size 3332 4327 2262 2330 1900 2275 1453 17,879
BMI (kg/m2) 24.4 ± 4.2 24.7 ± 4.1 24.6 ± 4.0 24.1 ± 4.0 24.5 ± 4.0 24.4 ± 4.0 24.3 ± 4.2 24.5 ± 4.1 6.68***
BMI (kg/m2)a 24.7 ± 0.1 25.1 ± 0.1 25.0 ± 0.1 24.7 ± 0.1 24.8 ± 0.1 24.8 ± 0.1 24.6 ± 0.1 NA 5.14***
BMI categories (%)
Normal 2050 (61.5) 2489 (57.5) 1326 (58.6) 1519 (65.2) 1137 (59.8) 1412 (62.1) 893 (61.5) 10,826 (60.5)
Overweight 1004 (30.2) 1407 (32.5) 718 (31.8) 636 (27.3) 601 (31.7) 674 (29.6) 425 (29.2) 5465 (30.6) 49.46***
Obese 278 (8.3) 431 (10.0) 218 (9.6) 175 (7.5) 162 (8.5) 189 (8.3) 135 (9.3) 1588 (8.9)
Smoking categories
Current 918 (27.6) 1148 (26.5) 603 (26.7) 680 (29.2) 551 (29.1) 623 (27.4) 389 (26.8) 4912 (27.5)
Former 847 (25.4) 1029 (23.8) 563 (24.9) 520 (22.3) 413 (21.8) 479 (21.1) 320 (22.0) 4171 (23.3) 32.17 *
Never 1567 (47.0) 2148 (49.7) 1095 (48.4) 1129 (48.5) 933 (49.2) 1173 (51.6) 744 (51.2) 8789 (49.2)
Tried to stop smoking 225 (24.5) 282 (24.6) 156 (25.9) 175 (25.7) 160 (29.0) 198 (31.8) 74 (19.0) 1270 (25.9) 25.67***
Hypertension (%)
Screening 2170 (65.1) 2815 (65.1) 1526 (67.5) 1502 (64.5) 1206 (63.5) 1494 (65.7) 972 (66.9) 11,685 (65.4) 10.10NS
Prevalence 843 (25.3) 1194 (27.6) 678 (30.0) 623 (26.7) 497 (26.2) 552 (24.3) 398 (27.4) 4785 (26.8) 24.96***
Treatmentb 553 (65.6) 777 (65.1) 430 (63.4) 397 (63.7) 285 (57.3) 357 (64.7) 264 (66.3) 3063 (64.0) 12.26 NS
Dyslipidemia (%)
Screening 1572 (47.2) 1907 (44.1) 969 (42.8) 937 (40.2) 729 (38.4) 862 (37.9) 756 (52.0) 7732 (43.2) 121.8***
Prevalence 730 (21.9) 825 (19.1) 434 (19.2) 447 (19.2) 308 (16.2) 412 (18.1) 333 (22.9) 3489 (19.5) 39.81***
Treatmentb 344 (47.1) 380 (46.1) 167 (38.5) 166 (37.1) 105 (34.1) 139 (33.7) 159 (47.8) 1460 (41.8) 43.98***
Diabetes (%)
Screening 1547 (46.4) 1969 (45.5) 1048 (46.3) 1038 (44.6) 818 (43.1) 976 (42.9) 759 (52.2) 8155 (45.6) 39.91***
Prevalence 193 (5.8) 255 (5.9) 137 (6.1) 132 (5.7) 87 (4.6) 92 (4.0) 77 (5.3) 973 (5.4) 15.84 *
Treatmentb 125 (64.8) 155 (60.8) 69 (50.4) 65 (49.2) 44 (50.6) 53 (57.6) 45 (58.4) 556 (57.1) 13.49 *
Results are expressed as mean ± SD or as number of patients and (percentage). NA, not assessable. Statistical analysis by analysis of variance or chi-square test:
NS; not significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001.a adjusted for gender, education, nationality and marital status; b drug treatment among subjects
reporting the risk factor
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regions (Table 2). As for obesity, no significant between-
region differences in current smoking levels were found
after multivariate adjustment for age, gender, education,
nationality and marital status (Table 3). One quarter of
current smokers reported having tried to quit within the
last 12 months, the percentage being highest in East and
Central Switzerland and lowest in Ticino (Table 2).
After multivariate adjustment, smokers from East and
Central Switzerland had a higher likelihood of reporting
they tried to quit: Odds ratio and [95% confidence inter-
val], 1.31 [1.03 - 1.67] and 1.46 [1.16 - 1.83] while no
difference was found for Ticino: 0.76 [0.56 - 1.02].
Hypertension
Almost two thirds of participants reported having their
blood pressure levels screened within the last 12
months, and no significant difference was found
between regions (Table 2), even after multivariate
adjustment for age, gender, marital status, educational
level, Swiss citizenship and attending a medical consul-
tation within the last 12 months (Table 4).
When asked about their blood pressure status, over
one quarter of participants reported being told they had
high blood pressure, and significant differences were
found between regions, North-West Switzerland pre-
senting the highest levels and Central Switzerland the
lowest (Table 2). After multivariate adjustment, a signifi-
cantly higher likelihood of reporting high blood pressure
was found for North-West Switzerland, while no differ-
ences were found for the other regions (Table 4).
Almost two thirds of subjects who had been told they
had high blood pressure also reported being treated, the
highest treatment rates being found for Ticino and the
lowest in East Switzerland (Table 2). These findings were
partly confirmed after multivariate adjustment, partici-
pants from East Switzerland presenting a lower likelihood
of being treated, while no differences were found for the
other regions (Table 4).
Dyslipidemia
Slightly over half of the participants reported having their
cholesterol levels screened within the last 12 months, with
considerable differences between regions. Participants liv-
ing in Ticino reported the highest screening levels, while
participants living in East and Central Switzerland
reported the lowest (Table 2). These findings were further
confirmed by multivariate adjustment, participants from
Ticino presenting a higher likelihood of being screened,
while participants from the other regions showed a lower
likelihood of being screened (Table 4).
Table 3 Multivariate analysis of the differences between
regions in obesity and smoking self-reported prevalence,
Switzerland, 2007
Obesity Smoking
Lemanic region 1 (ref.) 1 (ref.)
Mittelland 1.20
(1.02 - 1.41)
0.95
(0.86 - 1.06)
Northwest 1.18
(0.98 - 1.43)
1.01
(0.89 - 1.14)
Zurich 0.96
(0.79 - 1.17)
1.10
(0.98 - 1.25)
East 1.02
(0.84 - 1.26)
1.08
(0.94 - 1.22)
Central 1.01
(0.83 - 1.23)
0.99
(0.88 - 1.13)
Ticino 1.02
(0.82 - 1.27)
1.04
(0.90 - 1.20)
Results are expressed as odds ratio and (95% confidence interval). Adjusted
for age, gender, marital status, educational level and Swiss citizenship
Table 4 Multivariate analysis of differences between regions for self-reported cardiovascular risk factors, Switzerland,
2007
Hypertension Dyslipidemia Diabetes
Screening Prevalencea Treatmentb Screening Prevalencea Treatmentb Screening Prevalencea Treatmentb
Leman 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
Mittelland 1.00
(0.90 - 1.10)
1.10
(0.98 - 1.24)
0.93
(0.75 - 1.15)
0.86
(0.78 - 0.95)
0.83
(0.74 - 0.94)
0.80
(0.64 - 1.01)
0.95
(0.86 - 1.05)
0.98
(0.80 - 1.20)
0.74
(0.48 - 1.13)
Northwest 1.09
(0.96 - 1.23)
1.18
(1.03 - 1.35)
0.86
(0.67 - 1.09)
0.75
(0.67 - 0.85)
0.80
(0.69 - 0.92)
0.59
(0.45 - 0.78)
0.93
(0.83 - 1.05)
0.97
(0.77 - 1.23)
0.54
(0.33 - 0.88)
Zurich 0.97
(0.86 - 1.09)
1.11
(0.96 - 1.27)
0.86
(0.67 - 1.11)
0.72
(0.64 - 0.81)
0.86
(0.74 - 0.99)
0.53
(0.41 - 0.70)
0.93
(0.83 - 1.04)
0.99
(0.78 - 1.26)
0.54
(0.33 - 0.90)
East 1.00
(0.88 - 1.13)
1.07
(0.92 - 1.24)
0.65
(0.50 - 0.85)
0.69
(0.60 - 0.78)
0.71
(0.61 - 0.83)
0.46
(0.34 - 0.63)
0.90
(0.80 - 1.02)
0.78
(0.59 - 1.02)
0.55
(0.31 - 0.97)
Central 1.08
(0.96 - 1.22)
0.98
(0.85 - 1.13)
0.91
(0.70 - 1.18)
0.68
(0.61 - 0.77)
0.87
(0.75 - 1.00)
0.48
(0.36 - 0.63)
0.90
(0.80 - 1.02)
0.70
(0.54 - 0.92)
0.76
(0.44 - 1.33)
Ticino 1.11
(0.97 - 1.27)
0.94
(0.80 - 1.10)
0.89
(0.67 - 1.19)
1.18
(1.03 - 1.36)
0.96
(0.82 - 1.12)
0.87
(0.65 - 1.17)
1.24
(1.09 - 1.42)
0.78
(0.59 - 1.03)
0.71
(0.39 - 1.28)
Results are expressed as odds ratio and (95% confidence interval). Adjusted for age, gender, marital status, educational level, Swiss citizenship, BMI and smoking
status and consulted last 12 months; For a, a further adjustment for screening for the risk factor the last 12 months was performed; b drug treatment among
subjects reporting the risk factor
Marques-Vidal and Paccaud BMC Public Health 2012, 12:246
http://www.biomedcentral.com/1471-2458/12/246
Page 5 of 9
One-fifth of the participants reported being told they
had high cholesterol levels, and significant differences
were found between regions, the Leman presenting the
highest and East Switzerland the lowest rates (Table 2).
Multivariate adjustment showed that participants from
all regions (except Ticino) had a lower likelihood of
reporting being dyslipidemic than participants from
Leman (Table 4).
Four out of ten participants who had been told they
had high cholesterol levels also reported being treated.
Treatment rates were highest in Ticino and Leman and
lowest in East and Central Switzerland (Table 2), and
these findings were further confirmed by multivariate
adjustment (Table 4).
Diabetes
Less than half of the participants reported having their
blood glucose levels screened within the last 12 months,
the highest levels being found in Ticino and the lowest in
Central and East Switzerland (Table 2). After multivariate
adjustment, the participants living in Ticino had a higher
likelihood of having their blood glucose assessed, while
no differences were found for the other regions (Table 4).
Approximately 5% of all participants reported being
told they had diabetes, the highest values being found in
Zurich and the lowest in East Switzerland (Table 2).
After multivariate adjustment, only participants living in
East Switzerland had a lower likelihood of being told they
had diabetes, while no differences were found for the
other regions (Table 4).
Slightly less than six out of ten participants who had
been told they had diabetes reported being treated. The
highest treatment rates were found in the Lemanic area
and the lowest in Zurich (Table 2). These findings were
further confirmed by multivariate analysis, which showed
that participants from three regions (Zurich, North-West
and East Switzerland) to have a lower likelihood of being
treated (Table 4).
Discussion
To our knowledge, this is the first study to assess the geo-
graphical differences in cardiovascular risk factor screen-
ing and management in Switzerland. Our results indicate
that CVRF screening and management differ between
regions and that these differences cannot be accounted for
by differences in population age, gender, educational level
or migrant status, suggesting that other factors such as
local habits might be at stake.
On bivariate analysis, small differences in the preva-
lence of overweight and obesity were found between
regions, but these differences were no longer significant
after multivariate adjustment. Overall, our results indi-
cate that excess BMI is evenly distributed throughout
Switzerland, although a trend reversal has been shown
for Zurich [17]. Hence, it will be of interest to assess
regional trends in CVRFs, to assess if there are any
differences.
No regional differences were found regarding the
reported prevalence of smoking. It is possible that differing
smoking policies between cantons within a given region
might have reduced the differences between regions but, as
reported above, the number of participants for some can-
tons was too small to draw any valid conclusion. Conver-
sely, current smokers from East and Central Switzerland
had a higher likelihood of reporting they tried to quit.
Although quitting smoking might be more due to personal
motivations than to medical recommendations, our results
suggest that some local anti-smoking policies might induce
more smokers to try quitting than others. Still, as the pre-
valence of former smokers in these two regions (East and
Central Switzerland) was somewhat lower than in the
others, further studies are needed to better assess the actual
impact of local policies on smoking prevalence and trends.
No significant differences were found between regions
regarding hypertension screening and prevalence. Only
two thirds of participants who had been told they were
hypertensive reported being treated, a value lower than
observed in another Swiss population-based study [18].
Treatment rates were somewhat comparable between
regions, with the exception of East Switzerland, which
showed significantly lower treatment levels. A possible
explanation would be differing socio-economic character-
istics of this region as it has been reported in the UK [19],
but this hypothesis is rather unlikely as the differences per-
sisted after adjusting for educational level. Another expla-
nation is that health expenditures are lower in the cantons
composing this region [11,18], which could lead to lower
screening and management efforts; nevertheless, more
studies are welcomed to better assess this point. Overall,
our data suggest that (i) hypertension screening and man-
agement are relatively homogeneous within Swiss regions
and (ii) treatment rates could be improved.
Less than half of the participants reported having their
cholesterol levels screened the year before, and screening
was more frequently reported in French and Italian
speaking regions. Similarly, less than half of the partici-
pants who had been diagnosed with hypercholesterolemia
reported being treated, a finding in agreement with a pre-
vious study [20]. Again, most German-speaking regions
had significantly lower treatment levels than French or
Italian-speaking ones. Overall, our data suggest a clear
socio-cultural cleavage regarding screening and manage-
ment of hypercholesterolemia, practitioners living in
French and Italian-speaking regions being more sensi-
tized towards this risk factor. A possible explanation
might be the fact that, in Switzerland, the most used
equation to assess cardiovascular risk is PROCAM [21], a
German-based equation that has not been validated in
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women neither calibrated for the Swiss population. Con-
versely, the SCORE equation recommended by the Eur-
opean guidelines [22] which has been calibrated to the
Swiss population [23] and shown to present the best
cost-effectiveness [24] is seldom applied [21]. Other rea-
sons such as lower health expenditures in the German-
speaking regions [11,18] might also intervene, but further
studies are needed to better assess the rationale for these
regional differences in hypercholesterolemia management
and their possible consequences in cardiovascular disease
rates. Overall, our results indicate that in Switzerland, (i)
the German-speaking regions present lower treatment
rates for hypercholesterolemia, and (ii) less than half of
the participants diagnosed with hypercholesterolemia
actually benefit from drug treatment. It would be of
interest to implement the current European guidelines in
order to improve the management of hypercholesterole-
mia in Switzerland.
Less than half of the participants reported having their
blood glucose levels screened the year before, this per-
centage being higher in the South (Ticino). Similarly, less
than two thirds of the participants who had been told
they had diabetes reported being treated, a value lower
than previously reported [25]. As for hypercholesterole-
mia, most German-speaking regions had significantly
lower treatment levels than French or Italian-speaking
ones. These findings are partly in agreement with a pre-
vious study, which showed significant regional differences
in antidiabetic drug prescribing patterns and glycemic
control among patients with type 2 diabetes mellitus
[14]. Again, the rationale for such regional differences is
not clear and might be due to differences in medical
expenditures [11], or to differing practices. Overall, our
data indicate that (i) management of diabetes varies
according to region in Switzerland, the German-speaking
regions presenting lower treatment rates, and (ii) less
than two thirds of the participants diagnosed with dia-
betes actually benefit from drug treatment. Again, it
would be of interest to apply the current guidelines on
screening and management of diabetes [26-29] to opti-
mize outcome and health expenditures.
The between-regional differences observed regarding
CVD prevention might partly be due to differing local
health policies or to differing health insurance systems.
For instance, for most benefits covered by health insur-
ance, tariffs are set at national level for medical goods or
negotiated at cantonal level for services [30], leading to
different insurance premiums between cantons and/or
regions. Further, one third of the Swiss population also
contracted a private supplementary health insurance, and
over a thousand different supplementary health insurance
products existed in 2011 [30]. Finally, a recent OECD
report [30] concluded that the split governance between
cantons and the federal level leading to a lack of political
leadership and drive for reforms in the Swiss health sys-
tem; the report also concluded that Switzerland should
overcome co-ordination problems to define national poli-
cies for prevention and health promotion.
This study has some limitations. First, most data were
self-reported, which could lead to an underestimation of
the true prevalence of the main cardiovascular risk fac-
tors, as it has been shown that a significant percentage
of the population is not aware of their status
[8,18,20,25]. Conversely, it is possible that more healthy-
conscious subjects participated, which would increase
screening and treatment rates. Nevertheless, this would
not impact between-region differences and would sug-
gest that true screening and treatment rates are actually
lower than the ones presented, further increasing the
urge of implementation procedures. The main strengths
of this study is that it can be considered as representa-
tive of the Swiss population, it allowed to assess not
only prevalence but also screening and management of
the main CVRFs, and to adjust for a variety of co-fac-
tors, including educational level and medical consulta-
tions. It is also possible that some participants reporting
high levels of cardiovascular risk factors might not jus-
tify being treated as their overall cardiovascular risk, as
assessed by the common risk equations, might be below
the treatment threshold. Still, it has been shown that
non-calibrated CVD risk equations overestimate risk
among Swiss [31], which would prompt Swiss GPs to
treat their patients more frequently than actually
needed. Further, a recent survey conducted in 66 gen-
eral practices in 12 European countries showed that
blood pressure, lipid and glucose control are completely
inadequate with most patients not achieving the targets
defined in the prevention guidelines [32]. Hence, it is
likely that considerable progress can still be achieved
regarding CVD prevention in Switzerland. Finally,
although data obtained from Health Interview Surveys
parallel those obtained using examination surveys [33],
the best option would be to associate the results from a
Health Interview and a Health Examination Survey, as
the former allow the collection of objectively measured
data. Furthermore, the implementation of a standardized
Health Examination Surveys, based in questionnaires
and measurements, would allow a better comparison
between countries [34-36]. Still, the implementation of
such a study is costly, usually leading to a smaller sam-
ple size (with possible biases regarding minorities or
specific population groups), and despite recommenda-
tions [34] several European countries (Austria, Belgium,
Portugal...) never conducted such a survey. In Switzer-
land, the ongoing 2012 National Health Survey follows a
methodology similar to the previous ones2 and the
results will be compared to local or regional surveys
based on objectively measured data.
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Conclusion
In Switzerland, cardiovascular risk factor screening and
management differ between regions and these differences
cannot be accounted for by differences in populations’
characteristics. The impact of these differing health stra-
tegies on cardiovascular disease incidence and mortality
should be further assessed.
Endnotes
1http://www.bfs.admin.ch/bfs/portal/fr/index/themen/
16/04/key/approche_globale.indicator.30101.301.html?
open=2,1#1 (in French)
2http://www.bfs.admin.ch/bfs/portal/fr/index/infothek/
erhebungen__quellen/blank/blank/ess/01.html, assessed
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